■本文旨在通过检测hENT1水平,寻找合适的胰腺癌(PC)患者用吉西他滨治疗,具有更好的生存结果。
■我们收集了2004年9月至2014年12月在我院接受根治性手术的PC患者的手术病理组织。总共375个PC组织和配对的邻近非肿瘤组织用于构建4个组织微阵列(TMA)。通过HE染色检查4种TMA的质量。我们进行了免疫组织化学分析以评估TMA中hENT1的表达。此外,我们检测了hENT1的表达水平,证明了hENT1在细胞增殖中的作用,耐药性,体内和体外的迁移和侵袭。
■结果表明,hENT1低表达表明PC患者的预后明显较差,包括缩短的DFS(21.6±2.8个月对36.9±4.0个月,p<0.001)和OS(33.6±3.9对39.6±3.9,p=0.004)。同时,TNM分期I/II期患者的OS(40.2±3.4vs15.4±1.7,p=0.002)和DFS(31.0±3.1vs12.4±1.9,p=0.016)比III/IV期患者长.M0期患者的OS(39.7±3.4对16.2±1.9,p=0.026)和DFS(30.7±3.0对11.8±2.2,p=0.031)比M1期患者长,肿瘤未侵入胶囊的患者的DFS优于肿瘤侵入胶囊的患者(30.8±3.0对12.6±2.3,p=0.053)。术前CA19-9值≤467U/mL的患者的DFS高于术前CA19-9值>467U/mL的患者(37.9±4.1对22.9±4.0,p=0.04)。在亚组分析中,在吉西他滨亚组中,高hENT1表达水平与较长的OS(39.4±4.0vs31.5±3.9,p=0.001)和DFS(35.7±4.0vs20.6±2.7;p<0.0001)相关.
■hENT1高表达的PC患者在接受吉西他滨治疗时具有更好的生存结果。hENT1的表达可以成为PC患者接受吉西他滨治疗的重要预后指标。
UNASSIGNED: This article aimed to find appropriate pancreatic cancer (PC) patients to treat with Gemcitabine with better survival outcomes by detecting
hENT1 levels.
UNASSIGNED: We collected surgical pathological tissues from PC patients who received radical surgery in our hospital from September 2004 to December 2014. A total of 375 PC tissues and paired adjacent nontumor tissues were employed for the construction of 4 tissue microarrays (TMAs). The quality of the 4 TMAs was examined by HE staining. We performed immunohistochemistry analysis to evaluate
hENT1 expression in the TMAs. Moreover, we detected
hENT1 expression level and proved the role of
hENT1 in cell proliferation, drug resistance, migration and invasion in vivo and vitro.
UNASSIGNED: The results indicated that low
hENT1 expression indicated a significantly poor outcome in PC patients, including shortened DFS (21.6±2.8 months versus 36.9±4.0 months, p<0.001) and OS (33.6±3.9 versus 39.6±3.9, p=0.004). Meanwhile, patients in stage I/II of TNM stage had a longer OS (40.2±3.4 versus 15.4±1.7, p=0.002) and DFS (31.0±3.1 versus 12.4±1.9, p=0.016) than patients in stage III/IV. Patients in M0 stage had a longer OS (39.7±3.4 versus 16.2±1.9, p=0.026) and DFS(30.7±3.0 versus 11.8±2.2, p=0.031) than patients in M1 stage, and patients with tumors not invading the capsule had a better DFS than those with tumor invasion into the capsule (30.8±3.0 versus 12.6±2.3, p=0.053). Patients with preoperative CA19-9 values ≤467 U/mL have longer DFS than that of patients who had preoperative CA19-9 values >467 U/mL (37.9±4.1 versus 22.9±4.0, p=0.04). In the subgroup analysis, a high
hENT1 expression level was related to a longer OS(39.4±4.0 versus 31.5±3.9, p=0.001) and DFS(35.7±4.0 versus 20.6±2.7; p<0.0001) in the Gemcitabine subgroup.
UNASSIGNED: PC patients with high hENT1 expression have a better survival outcomes when receiving Gemcitabine. hENT1 expression can be a great prognostic indicator for PC patients to receive Gemcitabine treatment.